stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) Revenue
Arrowhead Pharmaceuticals, Inc.'s revenue for fiscal 2025 was $829.4M, up 23,258.2% from $3.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was $669.5M. Over the past ten years it has ranged from $158.3K (fiscal 2016) to $829.4M (fiscal 2025) — the current reading is the highest in ten years. Arrowhead Pharmaceuticals, Inc. ranks 36th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $829.4M | 23,258.15% |
| FY2024 | $3.6M | (98.52%) |
| FY2023 | $240.7M | (1.03%) |
| FY2022 | $243.2M | 75.89% |
| FY2021 | $138.3M | 57.16% |
| FY2020 | $88.0M | (47.87%) |
| FY2019 | $168.8M | 945.68% |
| FY2018 | $16.1M | (48.60%) |
| FY2017 | $31.4M | 19,740.62% |
| FY2016 | $158.3K | (58.56%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $75.3M | 2.06% |
| Mar 2026 | $73.7M | (72.07%) |
| Dec 2025 | $264.0M | 2.95% |
| Sep 2025 | $256.5M | 823.66% |
| 39 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MDGL Madrigal Pharmaceuticals, Inc. compare | $1.4B |
| CAI Caris Life Sciences,�Inc. compare | $1.0B |
| CORT Corcept Therapeutics Incorporated compare | $963.6M |
| ARWR Arrowhead Pharmaceuticals, Inc. | $669.5M |
| KRYS Krystal Biotech, Inc. compare | $470.0M |
| TWST Twist Bioscience Corporation compare | $431.8M |
| PTGX Protagonist Therapeutics, Inc. compare | $282.0M |
| CYTK Cytokinetics, Incorporated compare | $113.3M |
| SYRE Spyre Therapeutics, Inc. compare | $1.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ARWR
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement